Close
Smartlab Europe
Achema middle east

China Shenghuo Q2 sales climb 58%

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

- Advertisement -

China Shenghuo, engaged in the research, development, manufacture and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products, has reported sales of $10.9m for the second quarter ended 30 June 2011, an increase of 58% compared to $6.88m for the same period in 2010. The increase in sales was primarily due to the increase in company’s main product Xuesaitong in Tianjin City and Yunnan Province and enhanced sales promotion in Yunnan Province.China Shenghuo’s net income was $105,390, compared to net loss of $37,910 for the same period in the prior year.

The company’s income from operations was $556,930 for the second quarter ended 30 June 2011, compared to $334, 554 for the same period in 2010.For the six months ended 30 June 2011 sales were $20.34m, compared to $14.79m for the same period in 2010.Net loss was $191,091 for the six months ended 30 June 2011, as compared to $348,379 for the same period prior year.For the six months ended 30 June 2011, the company’s income from operations were $ 964,494 as compared to operating income of $ 348,379 for the same period in 2010.

Latest stories

Related stories

How APAC Biotech Plans to Turn 2026 Trends into Innovation While Managing Risk?

Asia-Pacific’s biotechnology landscape is not just growing it is...

Laboratory Equipment Outsourcing Through CDMOs: Strategic and Cost Implications

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »